How to appeal a denied claim for an experimental / investigational label.
When a plan denies a claim as experimental or investigational — “insufficient evidence of clinical effectiveness,” “not generally accepted in the relevant medical community,” “no well-established peer-reviewed literature,” “FDA off-label use,” “considered investigational for the patient's specific indication” — the appeal letter is built around three converging frameworks: the medical-necessity counterweight backed by peer-reviewed clinical evidence in the patient's actual condition (drug-class or modality-specific PMC-indexed trials, NIH-source systematic reviews, and specialty-society guidelines such as NCCN for oncology, AHA/ACC for cardiology, AAN for neurology); the ERISA § 503 full-and-fair review at 29 C.F.R. § 2560.503-1 — the carrier's burden to disclose the specific clinical-evidence basis under (j)(4) and produce the claims file under (m); and the federal external-review channel at 45 C.F.R. § 147.136(d), where the Independent Review Organization (IRO) decides the dispute de novo and the decision is binding on the plan. The right framework varies by clinical context: oncology, rare-disease, and FDA-approved-but-off-label contexts sit closest to the peer-reviewed literature, self-funded ERISA plans layer on the federal claims-procedure rule for the §2560.503-1 procedural defects, and fully-insured plans route through the state external-review statute in the enrollee's jurisdiction — Cal. Health & Safety Code §1370.4(d) in California, N.Y. Ins. Law §4914 in New York, 28 Tex. Admin. Code §3.1010 / Tex. Ins. Code §4201.206 in Texas.
01 · What an experimental / investigational denial looks like on the EOB
An experimental / investigational denial — and the peer-reviewed-evidence / §2560.503-1 / §147.136 framework that defeats it.
An experimental / investigational denial shows up in three recognizable shapes. First, an oncology regimen — a checkpoint inhibitor, a CAR-T cell therapy, a targeted-therapy combination, an off-label but FDA-approved use — where the carrier has applied the “experimental / investigational” label on a clinical-evidence basis the carrier refuses to disclose in detail. Second, a rare-disease treatment — an orphan-drug indication, a gene therapy, a high-cost specialty medication on a narrow indication — where the carrier has generalized the “experimental” determination from the broader class to the patient's specific case without engaging the patient-specific evidence on the medical record. Third, an FDA-approved drug or device used in a clinically accepted but off-label context — a medication approved for one indication being prescribed for another where specialty-society guidelines support the off-label use — where the carrier denies on the “not FDA-approved for this indication” rationale that does not survive the medical-necessity counterweight when peer-reviewed literature supports the off-label use. All three shapes share the same structural defect on the EOB: the carrier's clinical-evidence basis is generic, the determination does not engage patient-specific evidence, and the appeal letter's job is to force the carrier to disclose the specific basis and defend it against the patient's peer-reviewed literature.
The framework layered on a denied experimental / investigational claim varies by plan type and by the patient's jurisdictional venue. For ACA marketplace and fully-insured plans, the federal external-review channel at 45 C.F.R. § 147.136(d) runs in parallel with the carrier's internal appeal — the IRO decides the experimental/investigational dispute de novo on the medical record, the decision binds the plan, and the four-month external-review window runs from each new internal denial. For self-funded ERISA plans, the Department of Labor's claims-procedure rule at 29 C.F.R. § 2560.503-1 implements ERISA § 503 at 29 U.S.C. § 1133 — the “full and fair review” requirement, the carrier's burden to identify the medical or vocational experts whose advice the plan relied on under (j)(4), and the claimant's right to the claims file under (m) at no charge, in time to respond. For fully-insured plans, the controlling state external-review statute supplies a parallel binding channel — Cal. Health & Safety Code §1370.4(d) for Knox-Keene licensee plans (the California legislature carved experimental/investigational out as a separate IMR track from medical-necessity), N.Y. Ins. Law §4914 for NY DFS external appeals (experimental/investigational determinations within scope of the binding external appeal, reviewed by a same-specialty physician under 11 NYCRR 71.4), and 28 Tex. Admin. Code §3.1010 / Tex. Ins. Code §4201.206 for Texas TDI external review, paired with the Texas prompt-pay obligation at Tex. Ins. Code §§ 843.338 / 542.060.
A well-built experimental / investigational appeal letter pins the controlling framework to the clinical context, demands the carrier's specific clinical-evidence basis under §2560.503-1(j)(4), attaches peer-reviewed literature in the patient's actual condition (drug-class or modality-specific PMC-indexed clinical trials, NIH-source systematic reviews, and specialty-society guidelines such as NCCN for oncology, AHA/ACC for cardiology, AAN for neurology), and reserves the same-specialty-physician external review under §147.136(d) or under the controlling state external-review statute. The treating physician's clinical letter on the patient's specific condition — paired with the medical-literature citation — is the single strongest counterweight to the carrier's generic “experimental” label, and the appeal letter preserves the four-month external-review window, the claims-file right under §2560.503-1(m), and the civil action under ERISA §502(a) at 29 U.S.C. §1132(a)(1)(B) on exhaustion of internal and external review for self-funded plans. The letter branches on whether the dispute is at first-stage internal appeal (carrier's clinical-evidence review on the (j)(4) disclosure), at the federal IRO channel under §147.136(d) (de novo binding external review by a same-specialty physician), or at the controlling state external-review channel (§1370.4(d) in CA, §4914 in NY, 28 Tex. Admin. Code §3.1010 / Tex. Ins. Code §4201.206 in TX).
01 · The three counter-arguments
The peer-reviewed evidence / §2560.503-1 / §147.136 counter-argument framework — three named grounds the letter must build on.
01
Carrier's missing clinical-evidence basis — §2560.503-1(j)(4) disclosure demand
The carrier has applied the “experimental / investigational” label without disclosing the specific clinical-evidence basis — which peer-reviewed studies the clinical reviewer relied on, which specialty-society guidelines the reviewer considered or rejected, what specific clinical criteria the reviewer applied to the patient's condition. The Department of Labor's claims-procedure rule at 29 C.F.R. § 2560.503-1(j)(4) and its parallel at (h)(4) require the plan to disclose, in the Adverse Benefit Determination notice and on request, the medical or vocational experts whose advice the plan relied on — and the appeal letter's first move is to demand the specific clinical-evidence basis under (j)(4) on the record, in writing, in the time window the regulation sets. When the carrier cannot point to a specific clinical-evidence basis for the experimental/investigational determination that engages the patient's actual condition, the §2560.503-1(b)(1) “full and fair review” standard is not met and the determination is procedurally defective — the appeal frames the request as a procedural-defect reversal under the federal claims-procedure rule, not as a re-argument of the underlying coverage decision. The supporting documentation is the Adverse Benefit Determination notice itself, the appeal-request letter demanding (j)(4) disclosure, and the §2560.503-1(m) claims-file request that surfaces the carrier's internal clinical-evidence review.
02
Peer-reviewed literature in the patient's condition defeats a non-specific “experimental” label
The carrier's clinical reviewer has applied the “experimental / investigational” label by generalizing from a broader clinical context (a drug class, a treatment modality, a patient population) to the patient's actual condition, without engaging the patient-specific peer-reviewed evidence. The counterweight is the peer-reviewed literature in the patient's actual condition — drug-class or modality-specific PMC-indexed clinical trials (search PubMed Central for the drug name + the patient's condition; cite the trial by NCT identifier, journal, year), NIH-source systematic reviews (cite the Cochrane review or AHRQ comparative-effectiveness review by identifier), and specialty-society guidelines that explicitly address the patient's condition (NCCN guidelines for oncology, AHA/ACC guidelines for cardiology, AAN guidelines for neurology, ATS guidelines for pulmonology, IDSA guidelines for infectious disease). The supporting documentation is the peer-reviewed literature itself (attach the publication, the abstract, and the methods section that establishes the patient population matches the patient's actual condition), the treating physician's clinical letter on the patient's specific condition citing the literature, and the specialty-society guideline excerpt that addresses the indication. The dispute is then reframed from “is the treatment experimental” to “does the peer-reviewed literature in the patient's condition support the treatment's clinical effectiveness for the patient's specific indication.”
03
Treating physician's clinical letter + medical literature — the strongest single counterweight
The carrier has applied the “experimental / investigational” label without engaging the treating physician's clinical judgment on the patient's specific condition. The counterweight is the treating physician's clinical letter — a letter written on the physician's letterhead, signed, dated, and addressed to the carrier's clinical-review department — that (a) names the patient's specific condition, (b) explains why the prescribed treatment is clinically appropriate for the patient's actual condition (not for a generalized class), (c) cites the peer-reviewed literature in the patient's condition, (d) explains why the alternatives the carrier has identified (cheaper formulary alternatives, step-therapy alternatives, “watchful waiting”) are not clinically appropriate for the patient, and (e) requests the carrier's clinical reviewer to engage with the clinical letter on a same-specialty basis. Same-specialty review is the lever — under federal ACA external review at 45 C.F.R. § 147.136(d), under California DMHC IMR at Cal. Health & Safety Code §1370.4(d) (Knox-Keene licensee plans), and under NYDFS External Appeal at N.Y. Ins. Law §4914 + 11 NYCRR 71.4, the external reviewer must be a same-specialty physician (or a panel that includes a same-specialty physician) reviewing the experimental/investigational determination de novo on the medical record. The treating physician's clinical letter, paired with the peer-reviewed literature, is the evidentiary foundation for the same-specialty review.
01 · State experimental / investigational specifics
Three state regimes that govern an experimental / investigational determination on a fully-insured plan.
01
California · DMHC experimental/investigational IMR carve-out (Cal. Health & Safety Code § 1370.4(d))
CA §1370.4(d)
California DMHC Independent Medical Review has a separate statutory track for experimental / investigational determinations at Cal. Health & Safety Code § 1370.4(d) — the California legislature carved experimental / investigational out of the medical-necessity IMR track under § 1370.4(a) precisely because the clinical-evidence analysis is different (peer-reviewed literature, specialty-society guidelines, treating-physician clinical letter) than medical-necessity. The Knox-Keene licensee plan enrollee files a DMHC complaint at 1-888-466-2219 (www.dmhc.ca.gov) within 180 days of the final internal denial, requests § 1370.4(d) IMR specifically (not the § 1370.4(a) medical-necessity track), and the DMHC assigns the case to an IMR panel that includes a same-specialty physician reviewer. The IMR decision is binding on the carrier under § 1370.4 — the 7-day expedited § 1370.4(a) window (which also applies to experimental/investigational determinations where ongoing care is at stake) collapses the timeline to 7 calendar days, and the carrier has 3 business days to comply once the IMR overturns the denial. The appeal cites § 1370.4(d) directly, attaches the peer-reviewed literature in the patient's condition, and pairs the IMR request with the treating physician's clinical letter.
02
New York · DFS External Appeal — experimental/investigational within scope (N.Y. Ins. Law § 4914, 11 NYCRR 71.4)
NY §4914
New York DFS External Appeal at N.Y. Ins. Law § 4914 and its implementing regulation at 11 NYCRR 71.4 covers experimental/investigational determinations within the scope of the binding external appeal — the enrollee files a DFS External Appeal application within 4 months of the final internal denial, requests External Appeal on the experimental/investigational grounds, and the NYDFS assigns the case to a certified Approved Review Organization (ARO) whose panel includes a same-specialty physician reviewer. The ARO decision is binding on the carrier under § 4914 — and the expedited External Appeal under § 4914(c) (where ongoing care is at stake) collapses the timeline to 72 hours for expedited review or 7 calendar days for standard expedited. The appeal cites § 4914 + 11 NYCRR 71.4 directly, attaches the peer-reviewed literature in the patient's condition, the treating physician's clinical letter, and the specialty-society guideline excerpt that addresses the indication. NYDFS Consumer Hotline 1-800-342-3736 routes the enrollee to the External Appeal packet and the filing flow.
03
Texas · TDI external review + prompt-pay (28 Tex. Admin. Code § 3.1010, Tex. Ins. Code § 4201.206 + § 542.060)
TX TDI
Texas TDI external review for experimental/investigational determinations runs at 28 Tex. Admin. Code § 3.1010 and Tex. Ins. Code § 4201.206 — the TDI assigns an Independent Review Organization (IRO) to evaluate the experimental/investigational determination, and the IRO decision is binding on the carrier. The enrollee files an external-review request with TDI within 4 months of the final internal denial (§ 4201.206(a)), the IRO completes review within 15 days for standard external review and within 5 days for expedited review (§ 4201.206(d)), and the carrier has 30 days from receipt of the external-review decision to comply. The parallel Texas prompt-pay obligation at Tex. Ins. Code § 542.060 (15-day acknowledgment window, 30-day claim-payment window for clean claims) and at Tex. Ins. Code § 843.338 for HMOs brackets the experimental/investigational dispute in carrier-payment timelines — the appeal pairs § 4201.206 external review with § 542.060 / § 843.338 prompt-pay when the carrier has failed to pay the claim within the statutory window. TDI complaint pathway (1-800-252-3439, tdi.texas.gov) routes the enrollee to the external-review packet and the filing flow.
01 · ERISA procedural note
For self-funded ERISA plans — the arbitrary-denial standard at 29 C.F.R. § 2560.503-1 plus the federal external-review channel at 45 C.F.R. § 147.136.
Self-funded ERISA plans — typically larger employer group plans where the employer pays the claims rather than buying insurance from a carrier — run through the Department of Labor's claims-procedure rule at 29 C.F.R. § 2560.503-1, implementing ERISA § 503 at 29 U.S.C. § 1133. The regulation requires the plan to give the claim a “full and fair review,” and the implementing language at § 2560.503-1(b)(1) prohibits denials that are “arbitrary and capricious.” On an experimental/investigational denial, the (b)(1) standard has three operational prongs the plan must satisfy: (i) the carrier must identify the specific clinical-evidence basis for the experimental/investigational determination under (j)(4) and (h)(4), naming the medical or vocational experts whose advice the plan relied on; (ii) the carrier's clinical reviewer must engage with the patient's specific condition (a same-specialty reviewer where clinical complexity demands it); and (iii) the carrier's conclusion must follow from the cited clinical evidence on the medical record, including the peer-reviewed literature and the treating physician's clinical letter. The ACA external-review channel at 45 C.F.R. § 147.136 still applies to self-funded ERISA plans on the experimental/investigational question — the federal IRO reviews the determination de novo under § 147.136(d), the IRO decision binds the plan, and the four-month external-review window runs from each new internal denial. The appeal letter pairs the § 2560.503-1 procedural-defect framing with the § 147.136(d) external-review reservation so that the carrier cannot shield an arbitrary experimental/investigational determination behind the plan-document framework.
The arbitrary-denial standard is the lever that distinguishes an experimental/investigational denial from a denial the plan must defend on the record. Specifically, the plan must show (i) that its clinical reviewer applied specific clinical criteria to the patient's specific condition (not a generalized “experimental” label), (ii) that the clinical-evidence basis cited by the reviewer under (j)(4) has been disclosed on the claim file, (iii) that the reviewer engaged with the peer-reviewed literature in the patient's condition that the treating physician cited in the clinical letter, and (iv) that the (m) claims-file right produces the documents, records, and other information relevant to the claim — including the internal clinical-review memorandum, the specialty-society guidelines consulted, and the reviewer qualifications. When any of those four are missing, the § 2560.503-1(b)(1) standard is not met on the experimental/investigational determination, and the appeal frames the ask as a procedural-defect reversal — pair the federal external-review reservation at 45 C.F.R. § 147.136(d) for the binding IRO decision, and the civil action under ERISA § 502(a) at 29 U.S.C. § 1132(a)(1)(B) for the follow-on right after exhaustion of internal and external review.
01 · Worked sample paragraph
A first-person appeal paragraph that has already survived one round.
Below is a worked survivor-language paragraph — the kind of letter a member writes after a carrier has adjudicated a claim on the “experimental / investigational” basis and refused to engage with the peer-reviewed literature in the patient's condition. The voice is first-person, the evidence is attached, and the citations frame the request as a procedural-defect reversal under § 2560.503-1(j)(4)/(m), a federal IRO external review under 45 C.F.R. § 147.136(d), and the controlling state external-review channel in the enrollee's jurisdiction. The sample subject is a denied oncology regimen — a checkpoint inhibitor prescribed off-label on the basis of NCCN guideline support — where the carrier has applied the “experimental / investigational” label without disclosing the specific clinical-evidence basis on the (j)(4) notice.
Re: Second-stage internal appeal — experimental / investigational denial for [TREATMENT], EOB dated [DATE]
I am writing as the patient and as the party who has previously filed a first-stage appeal of this denial. The plan's determination dated [DATE] denied coverage of [TREATMENT] on the basis that the treatment is “experimental / investigational” for the patient's condition. The Adverse Benefit Determination notice did not identify the specific clinical-evidence basis the plan relied on — which peer-reviewed studies, which specialty-society guidelines, which clinical criteria the clinical reviewer applied — as required under 29 C.F.R. § 2560.503-1(j)(4) and the parallel at (h)(4). The first-stage appeal was denied without addressing the peer-reviewed literature in the patient's condition that the treating physician had submitted, without engaging the treating physician's clinical letter on the patient's specific condition, and without identifying a same-specialty clinical reviewer who evaluated the determination. The determination did not engage the National Comprehensive Cancer Network (NCCN) guideline that supports [TREATMENT] for [INDICATION], nor the peer-reviewed clinical trial [CITATION, JOURNAL, YEAR] that establishes clinical effectiveness for the patient population.
I am submitting additional evidence to satisfy the full and fair review required under ERISA § 503 at 29 C.F.R. § 2560.503-1(b)(1) (where applicable) and the federal external-review channel at 45 C.F.R. § 147.136. Specifically: (1) the treating physician's clinical letter, dated [DATE], on letterhead, addressing the patient's specific condition, the clinical appropriateness of [TREATMENT] for [INDICATION], and the peer-reviewed literature in the patient's condition, attached as Exhibit A; (2) the peer-reviewed clinical trial [CITATION, JOURNAL, YEAR], attached as Exhibit B, establishing clinical effectiveness for the patient population; (3) the NCCN guideline excerpt for [INDICATION], attached as Exhibit C, that supports [TREATMENT] for the patient's condition; (4) the additional peer-reviewed literature in the patient's condition, attached as Exhibits D–F; and (5) a formal request under 29 C.F.R. § 2560.503-1(j)(4) for the plan to disclose, on the record, the specific clinical-evidence basis the clinical reviewer relied on and the medical or vocational experts whose advice the plan relied on. I am also formally requesting the (m) claims file — the documents, records, and other information relevant to the claim, free of charge, in time to respond.
I am requesting (a) a reversal of the experimental/investigational determination on procedural-defect grounds under 29 C.F.R. § 2560.503-1(j)(4)/(m)/(b)(1) and on the peer-reviewed-evidence counterweight cited above, (b) disclosure under (j)(4) of the specific clinical-evidence basis and the medical or vocational experts whose advice the plan relied on, (c) production of the (m) claims file including the internal clinical-review memorandum, the specialty-society guidelines consulted, and the reviewer qualifications, (d) initiation of federal external review by a same-specialty physician IRO under 45 C.F.R. § 147.136(d), and (e) preservation of the controlling state external-review channel in my jurisdiction — Cal. Health & Safety Code § 1370.4(d) DMHC experimental/investigational IMR in CA, N.Y. Ins. Law § 4914 + 11 NYCRR 71.4 NYDFS External Appeal in NY, 28 Tex. Admin. Code § 3.1010 / Tex. Ins. Code § 4201.206 TDI external review in TX, and the parallel foreign-state channel. Expedited review under 45 C.F.R. § 147.136(b)(3) (federal) or under § 2560.503-1(f)(2) (ERISA urgent-claim framing) is preserved where ongoing care is at stake. If the plan maintains the denial, I am preserving the civil action under ERISA § 502(a) at 29 U.S.C. § 1132(a)(1)(B) on exhaustion of internal and external review.
Cited: 45 C.F.R. § 147.136; 29 C.F.R. § 2560.503-1(b), (j)(4), (h)(4), (m); 29 U.S.C. §§ 1133, 1132(a)(1)(B); Cal. Health & Safety Code § 1370.4(d); N.Y. Ins. Law § 4914; Tex. Ins. Code §§ 4201.206, 542.060.
Identifiers, member IDs, claim numbers, treating physician names, drug names, NCT identifiers, guideline references, and journal citations in the sample paragraph above are placeholders — every name and number is invented, and only the controlling statute / CFR / USC citations are real (those are public law).
02 · Frequently asked
The §147.136 / §2560.503-1 / state external-review frameworks that govern an experimental / investigational denial.
Cited: 45 C.F.R. § 147.136 (federal external review) · 29 C.F.R. § 2560.503-1(j)(4), (m) (ERISA claims-procedure rule, clinical-evidence disclosure + claims-file right) · Cal. Health & Safety Code § 1370.4(d) (CA DMHC experimental/investigational IMR) · N.Y. Ins. Law § 4914 + 11 NYCRR 71.4 (NY DFS External Appeal) · Tex. Ins. Code § 4201.206 + 28 Tex. Admin. Code § 3.1010 (TX TDI external review).
Browse by state
Pick your state to see the appeal framework that applies.
Every state has a different agency, timeline, and binding external-review channel — start with yours.
03 · Submit the experimental / investigational denial
The same experimental / investigational denial — defended with the §147.136 / §2560.503-1 / state-external-review framework.
Upload the EOB or denial letter, answer the four short intake questions, and Denvow picks the federal external-review framework at 45 C.F.R. § 147.136(d) (the IRO reviews the experimental/investigational determination de novo, the IRO decision binds the plan, the four-month external-review window runs from each new internal denial), the ERISA claims-procedure rule at 29 C.F.R. § 2560.503-1 (the (j)(4) demand for the carrier's specific clinical-evidence basis, the (m) claims-file right, the (b)(1) full-and-fair-review standard), and the controlling state external-review channel in your jurisdiction (Cal. Health & Safety Code § 1370.4(d) for Knox-Keene licensee plans in CA, N.Y. Ins. Law § 4914 + 11 NYCRR 71.4 NYDFS External Appeal in NY, 28 Tex. Admin. Code § 3.1010 / Tex. Ins. Code § 4201.206 TDI external review in TX, and the parallel foreign-state channel) — and the letter branches on whether you are at the first-stage internal appeal, the federal § 147.136(d) IRO channel, or the controlling state external-review channel, with the peer-reviewed literature in the patient's condition (PMC-indexed clinical trials, NIH-source systematic reviews, specialty-society guidelines such as NCCN for oncology, AHA/ACC for cardiology, AAN for neurology) and the treating physician's clinical letter as the evidentiary foundation for the same-specialty external review.
Already in the intake? Pre-selected to “experimental-investigational” as the Segment-Denial-Reason — answer the rest and submit.
Other denial-reason pages
Denvow is template-and-tooling, not legal counsel. For denials that genuinely need litigation, an ERISA fiduciary complaint, or a state-court remedy, we recommend a licensed attorney in the relevant jurisdiction — and will say so when we see one.